Physiological organization of immune response based on the homeostatic mechanism of matrix reprogramming: Implication in tumor and biotechnology |
| |
Affiliation: | 1. Moscow State University of Medicine and Dentistry, Delegatskaya Str. 20/1, Moscow 127473, Russia;2. Institute of General Pathology and Pathophysiology, Baltijskaya 8, Moscow 125315, Russia;3. University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, TX 76107, USA;4. Moscow State University, GSP-1, Leninskie Gory Str., Moscow 119991, Russia |
| |
Abstract: | It is accepted that the immune system responds to pathogens with activation of antigen-independent innate and antigen-dependent adaptive immunity. However many immune events do not fit or are even inconsistent with this notion. We developed a new homeostatic model of the immune response. This model consists of four units: a sensor, a regulator, an effector and a rehabilitator. The sensor, macrophages or lymphocytes, recognize pathogenic cells and generate alarm signals. The regulator, antigen-presenting cells, Тregs and myeloid-derived suppressor cells, evaluate the signals and together with sensor cells program the effector. The effector, programmed macrophages and lymphocytes, eliminate the pathogenic cells. The rehabilitator, M2 macrophages, restrict inflammation, provide angiogenesis and reparation of tissue damage, and restore the homeostasis. We suggest the terms “immune matrix” for a biological template of immune responses to pathogens and “matrix reprogramming” for the interdependent reprogramming of different cells in the matrix. In an adequate immune response, the matrix forms a negative feedback mechanism to support the homeostasis. We defined the cellular and phenotypic composition of a tumor immune matrix. A tumor reprograms the homeostatic negative feedback mechanism of matrix into a pathogenic positive feedback mechanism. M2 macrophages play a key role in this transformation. Therefore, macrophages are an attractive target for biotechnology. Based on our hypotheses, we are developing a cell biotechnology method for creation of macrophages with a stable antitumor phenotype. We have shown that such macrophages almost doubled the survival time of mice with tumor. |
| |
Keywords: | APC" },{" #name" :" keyword" ," $" :{" id" :" k0375" }," $$" :[{" #name" :" text" ," _" :" antigen-presenting cell MHC-I and MHC-II" },{" #name" :" keyword" ," $" :{" id" :" k0385" }," $$" :[{" #name" :" text" ," _" :" major histocompatibility complex molecules class I and II, respectively NK cells" },{" #name" :" keyword" ," $" :{" id" :" k0395" }," $$" :[{" #name" :" text" ," _" :" natural killer cells T, Th0, Th1 and Th2" },{" #name" :" keyword" ," $" :{" id" :" k0405" }," $$" :[{" #name" :" text" ," _" :" Т, Th0, Th1 and Th2 cells, respectively CD" },{" #name" :" keyword" ," $" :{" id" :" k0415" }," $$" :[{" #name" :" text" ," _" :" cluster of differentiation М1 and М2" },{" #name" :" keyword" ," $" :{" id" :" k0425" }," $$" :[{" #name" :" text" ," _" :" macrophages of М1 and М2 phenotypes, respectively COPD" },{" #name" :" keyword" ," $" :{" id" :" k0435" }," $$" :[{" #name" :" text" ," _" :" chronic obstructive pulmonary disease IL" },{" #name" :" keyword" ," $" :{" id" :" k0445" }," $$" :[{" #name" :" text" ," _" :" interleukin TNF-α" },{" #name" :" keyword" ," $" :{" id" :" k0455" }," $$" :[{" #name" :" text" ," _" :" tumor necrosis factor-α IFN-γ" },{" #name" :" keyword" ," $" :{" id" :" k0465" }," $$" :[{" #name" :" text" ," _" :" interferon-γ TGF-β" },{" #name" :" keyword" ," $" :{" id" :" k0475" }," $$" :[{" #name" :" text" ," _" :" transforming growth factor-β ROS" },{" #name" :" keyword" ," $" :{" id" :" k0485" }," $$" :[{" #name" :" text" ," _" :" reactive oxygen species NO" },{" #name" :" keyword" ," $" :{" id" :" k0495" }," $$" :[{" #name" :" text" ," _" :" nitric oxide TLR" },{" #name" :" keyword" ," $" :{" id" :" k0505" }," $$" :[{" #name" :" text" ," _" :" toll-like receptor CTL" },{" #name" :" keyword" ," $" :{" id" :" k0515" }," $$" :[{" #name" :" text" ," _" :" cytotoxic antigen-specific Т cells Treg" },{" #name" :" keyword" ," $" :{" id" :" k0525" }," $$" :[{" #name" :" text" ," _" :" CD4+CD25+ T regulatory cells MDSC" },{" #name" :" keyword" ," $" :{" id" :" k0535" }," $$" :[{" #name" :" text" ," _" :" myeloid-derived suppressor cell TAM" },{" #name" :" keyword" ," $" :{" id" :" k0545" }," $$" :[{" #name" :" text" ," _" :" tumor-associated macrophages HSP70" },{" #name" :" keyword" ," $" :{" id" :" k0555" }," $$" :[{" #name" :" text" ," $$" :[{" #name" :" __text__" ," _" :" heat shock protein with molecular weight 70" },{" #name" :" hsp" ," $" :{" sp" :" 0.25" }},{" #name" :" __text__" ," _" :" kDa EGF" },{" #name" :" keyword" ," $" :{" id" :" k0575" }," $$" :[{" #name" :" text" ," _" :" epidermal growth factor PDGF" },{" #name" :" keyword" ," $" :{" id" :" k0585" }," $$" :[{" #name" :" text" ," _" :" platelet-derived growth factor HGF" },{" #name" :" keyword" ," $" :{" id" :" k0595" }," $$" :[{" #name" :" text" ," _" :" hepatocyte growth factor bFGF" },{" #name" :" keyword" ," $" :{" id" :" k0605" }," $$" :[{" #name" :" text" ," _" :" basic fibroblast growth factor MMP" },{" #name" :" keyword" ," $" :{" id" :" k0615" }," $$" :[{" #name" :" text" ," _" :" matrix metalloproteinase MIF" },{" #name" :" keyword" ," $" :{" id" :" k0625" }," $$" :[{" #name" :" text" ," _" :" macrophage migration inhibitory factor EMMPRIN" },{" #name" :" keyword" ," $" :{" id" :" k0635" }," $$" :[{" #name" :" text" ," _" :" extracellular matrix metalloproteinase inducer CSF-1" },{" #name" :" keyword" ," $" :{" id" :" k0645" }," $$" :[{" #name" :" text" ," _" :" macrophage colony-stimulating factor 1 VEGF" },{" #name" :" keyword" ," $" :{" id" :" k0655" }," $$" :[{" #name" :" text" ," _" :" vascular endothelial growth factor G-CSF" },{" #name" :" keyword" ," $" :{" id" :" k0665" }," $$" :[{" #name" :" text" ," _" :" granulocyte colony-stimulating factor GM-CSF" },{" #name" :" keyword" ," $" :{" id" :" k0675" }," $$" :[{" #name" :" text" ," _" :" granulocyte–macrophage colony-stimulating factor uPAR" },{" #name" :" keyword" ," $" :{" id" :" k0685" }," $$" :[{" #name" :" text" ," _" :" urokinase-type plasminogen activator receptor uPA" },{" #name" :" keyword" ," $" :{" id" :" k0695" }," $$" :[{" #name" :" text" ," _" :" urokinase-type plasminogen activator HAF" },{" #name" :" keyword" ," $" :{" id" :" k0705" }," $$" :[{" #name" :" text" ," _" :" human angiogenic factor HIF-1" },{" #name" :" keyword" ," $" :{" id" :" k0715" }," $$" :[{" #name" :" text" ," _" :" hypoxia-inducible factor |
本文献已被 ScienceDirect 等数据库收录! |
|